BAVARIAN NORDIC/S (OTCMKTS:BVNRY) released its earnings results on Wednesday. The company reported ($0.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.04), Morningstar.com reports. BAVARIAN NORDIC/S had a negative net margin of 126.80% and a negative return on equity of 19.43%. The company had revenue of $19.29 million for the quarter, compared to the consensus estimate of $21.15 million.
BAVARIAN NORDIC/S stock opened at $7.62 on Friday. BAVARIAN NORDIC/S has a twelve month low of $5.92 and a twelve month high of $10.78. The company has a quick ratio of 5.84, a current ratio of 6.15 and a debt-to-equity ratio of 0.17.
Separately, Zacks Investment Research downgraded shares of BAVARIAN NORDIC/S from a “buy” rating to a “hold” rating in a research report on Wednesday, March 6th.
Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus.
Featured Story: What strategies should day traders use to execute a trade?
Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with MarketBeat.com's FREE daily email newsletter.